Latest Headlines

Latest Headlines

IDM outlines big layoff in restructuring plan

Two weeks after it was jilted in a key drug collaboration deal, IDM Pharma

AstraZeneca drops cancer program after Phase II failure

AstraZeneca says it won't take the advanced melanoma drug AZD6244--licensed from Array BioPharma--into late stage trials after seeing the program flunk Phase II. Researchers said they could see no

Medarex shares dive after a cancer trial failure

Shares of Medarex took a dive in after-hours trading after the biotech announced that the cancer drug ipilimumab--

BMS misses a beat in cancer comeback

Amid the upbeat tone to yesterday's release of third quarter income at Bristol-Myers Squibb, executives hit a sour note with their announcement that they would probably not seek FDA approval of their

Synta therapy slows spread of melanoma

Lexington, MA-based Synta Pharmaceuticals caused quite a stir with a recent presentation on an early-stage cancer therapy that slowed the spread of aggressive skin cancer. In the Phase IIb trial,